NO971546L - Reumatoid artritt-middel inneholdende IL-6-antagonist som aktiv bestanddel - Google Patents

Reumatoid artritt-middel inneholdende IL-6-antagonist som aktiv bestanddel

Info

Publication number
NO971546L
NO971546L NO971546A NO971546A NO971546L NO 971546 L NO971546 L NO 971546L NO 971546 A NO971546 A NO 971546A NO 971546 A NO971546 A NO 971546A NO 971546 L NO971546 L NO 971546L
Authority
NO
Norway
Prior art keywords
rheumatoid arthritis
antagonist
active ingredient
agent containing
arthritis agent
Prior art date
Application number
NO971546A
Other languages
English (en)
Other versions
NO321089B1 (no
NO971546D0 (no
Inventor
Tadamitsu Kishimoto
Masahiko Mihara
Yoichiro Moriya
Yoshiyuki Ohsugi
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17112746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO971546(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Tadamitsu Kishimoto filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO971546D0 publication Critical patent/NO971546D0/no
Publication of NO971546L publication Critical patent/NO971546L/no
Publication of NO321089B1 publication Critical patent/NO321089B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO19971546A 1994-10-07 1997-04-04 Anvendelse av et interleukin-6 antistoff eller interleukin-6 reseptorantistoff for fremstilling av en farmasoytisk blanding for behandling av unormal synovialcelle-vekst. NO321089B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24403594 1994-10-07
PCT/JP1995/001144 WO1996011020A1 (en) 1994-10-07 1995-06-07 Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient

Publications (3)

Publication Number Publication Date
NO971546D0 NO971546D0 (no) 1997-04-04
NO971546L true NO971546L (no) 1997-06-04
NO321089B1 NO321089B1 (no) 2006-03-13

Family

ID=17112746

Family Applications (4)

Application Number Title Priority Date Filing Date
NO19971546A NO321089B1 (no) 1994-10-07 1997-04-04 Anvendelse av et interleukin-6 antistoff eller interleukin-6 reseptorantistoff for fremstilling av en farmasoytisk blanding for behandling av unormal synovialcelle-vekst.
NO20055446A NO20055446L (no) 1994-10-07 2005-11-17 Anvendelse av et interleukin-6 reseptorantistoff for fremstilling av en farmasoytisk blanding for behandlingav kronisk reumatoid artritt
NO2009009C NO2009009I2 (no) 1994-10-07 2009-05-04 Tocilizumab
NO2018017C NO2018017I1 (no) 1994-10-07 2018-05-23 Interleukin-6 (IL-6) reseptor antistoff (Krav 1 i NO321089). Forlenget SPC

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20055446A NO20055446L (no) 1994-10-07 2005-11-17 Anvendelse av et interleukin-6 reseptorantistoff for fremstilling av en farmasoytisk blanding for behandlingav kronisk reumatoid artritt
NO2009009C NO2009009I2 (no) 1994-10-07 2009-05-04 Tocilizumab
NO2018017C NO2018017I1 (no) 1994-10-07 2018-05-23 Interleukin-6 (IL-6) reseptor antistoff (Krav 1 i NO321089). Forlenget SPC

Country Status (18)

Country Link
EP (3) EP0783893B1 (no)
JP (1) JP3067987B2 (no)
KR (1) KR100306517B1 (no)
CN (2) CN101361972B (no)
AT (1) ATE552012T1 (no)
AU (1) AU700819B2 (no)
CA (1) CA2201781C (no)
CZ (1) CZ296919B6 (no)
DK (1) DK0783893T3 (no)
ES (1) ES2384222T3 (no)
FI (1) FI120721B (no)
HU (1) HU223602B1 (no)
LU (1) LU92048I2 (no)
NO (4) NO321089B1 (no)
PL (1) PL186506B1 (no)
PT (1) PT783893E (no)
RU (1) RU2147443C1 (no)
WO (1) WO1996011020A1 (no)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312184T3 (es) * 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
KR20100068498A (ko) * 1997-08-15 2010-06-23 츄가이 세이야꾸 가부시키가이샤 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제
PT1074268E (pt) 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
JP4318321B2 (ja) 1998-04-17 2009-08-19 インターナショナル フラワー ディベロプメンツ プロプラ イアタリー リミティド オーロン合成活性を有する蛋白質をコードする遺伝子
WO2002034292A1 (fr) 2000-10-25 2002-05-02 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
US20050074434A1 (en) * 2001-02-23 2005-04-07 Tomoaki Hoshino Remedies for metabolic bone diseases
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
ATE412013T1 (de) * 2001-04-05 2008-11-15 Immuno Biological Lab Co Ltd Anti-osteopontin-antikörper und dessen verwendung
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP2007104901A (ja) * 2004-01-16 2007-04-26 Astellas Pharma Inc 関節リウマチ治療薬のスクリーニング法
DE602005020743D1 (de) * 2004-02-11 2010-06-02 Warner Lambert Co Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
RU2293559C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ подготовки к любрикантной терапии
RU2293560C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ лечения хронических гонартритов у больных остеоартрозом
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US20110027220A1 (en) * 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
AU2007282023B2 (en) 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
JP2010095445A (ja) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2724279C (en) 2008-05-13 2017-03-07 Novimmune S.A. Anti-il-6/il-6r antibodies and methods of use thereof
TWI528973B (zh) * 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
RU2011151069A (ru) 2009-05-15 2013-06-20 Чугаи Сейяку Кабусики Кайся Анти-axl антитело
CN102427822A (zh) * 2009-05-18 2012-04-25 香港大学 治疗炎症性关节炎的组合物和方法
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
JP4987117B2 (ja) 2010-12-27 2012-07-25 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
WO2013176471A1 (ko) 2012-05-21 2013-11-28 한국생명공학연구원 곰보배추의 추출물 또는 이의 분획물을 유효성분으로 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
PL3299810T3 (pl) 2015-05-19 2021-12-13 National Center Of Neurology And Psychiatry Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
EP3305325B1 (en) 2015-06-04 2025-07-30 National Center of Neurology and Psychiatry Mental illness therapeutic agent having il-6 inhibitor as active ingredient
SG11201803654TA (en) 2015-11-03 2018-05-30 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
CA3016424A1 (en) 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
ES3055961T3 (en) 2016-04-28 2026-02-17 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
CN108339118A (zh) * 2017-01-23 2018-07-31 瑞阳(苏州)生物科技有限公司 治疗或预防阻塞性睡眠呼吸暂停的药物组合物
EP3603670A4 (en) 2017-03-31 2021-03-10 Public University Corporation Nara Medical University MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
MX2020002750A (es) 2017-09-13 2020-07-20 Jiangsu Hengrui Medicine Co Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
TW202600611A (zh) 2017-11-01 2026-01-01 日商中外製藥股份有限公司 生物活性降低之抗體變異體與同功型
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
MA53481A (fr) 2018-08-29 2021-07-07 Regeneron Pharma Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde
CN109517064B (zh) * 2018-10-10 2020-05-08 北京汇智和源生物技术有限公司 白介素-6的人源化单克隆抗体、其编码基因及应用
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CN114651010A (zh) 2019-04-24 2022-06-21 赛诺菲生物技术公司 类风湿性关节炎的诊断和治疗方法
KR20230061198A (ko) 2019-06-04 2023-05-08 사노피 바이오테크놀로지 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법
TWI872251B (zh) 2020-05-29 2025-02-11 日商中外製藥股份有限公司 含有抗體製劑

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
EP0399429A1 (en) * 1989-05-22 1990-11-28 Toray Industries, Inc. Anti-human interleukin-6 monoclonal antibody
ATE144713T1 (de) * 1989-07-20 1996-11-15 Tadamitsu Kishimoto Antikörper gegen menschlichen interleukin-6- rezeptor
JP2898064B2 (ja) 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
DE3939706C1 (no) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
AU648777B2 (en) * 1989-12-04 1994-05-05 Schering Corporation Method of treating septic shock
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
JPH0489433A (ja) 1990-07-27 1992-03-23 Hitachi Chem Co Ltd 免疫調節剤
JP2947924B2 (ja) * 1990-11-21 1999-09-13 信和化工株式会社 光学異性体用分離剤
JPH04187645A (ja) * 1990-11-22 1992-07-06 Chuzo Kishimoto インターロイキン―６作用抑制剤
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
JPH05300338A (ja) 1992-04-17 1993-11-12 Ricoh Co Ltd 複合機
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
JPH06134617A (ja) 1992-10-23 1994-05-17 Amada Co Ltd 鋸盤の鋸刃テンション自動調整装置
JP3525221B2 (ja) * 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤

Also Published As

Publication number Publication date
HUT77036A (hu) 1998-03-02
CN101361972A (zh) 2009-02-11
CZ296919B6 (cs) 2006-07-12
AU700819B2 (en) 1999-01-14
EP2107070A1 (en) 2009-10-07
DK0783893T3 (da) 2012-05-29
WO1996011020A1 (en) 1996-04-18
PL319574A1 (en) 1997-08-18
EP0783893A4 (en) 1998-04-22
FI971404L (fi) 1997-06-03
KR100306517B1 (ko) 2001-11-30
PT783893E (pt) 2012-05-24
JP3067987B2 (ja) 2000-07-24
CN101361972B (zh) 2011-05-25
CA2201781C (en) 2010-01-12
ATE552012T1 (de) 2012-04-15
NO20055446L (no) 1997-06-04
HU223602B1 (hu) 2004-10-28
CA2201781A1 (en) 1996-04-18
CZ103497A3 (en) 1997-08-13
NO321089B1 (no) 2006-03-13
FI120721B (fi) 2010-02-15
ES2384222T3 (es) 2012-07-02
HK1127497A1 (en) 2009-09-25
NO2018017I1 (no) 2018-05-23
AU2630395A (en) 1996-05-02
EP2077120A3 (en) 2009-07-15
EP2077120A2 (en) 2009-07-08
NO2009009I2 (no) 2013-03-18
RU2147443C1 (ru) 2000-04-20
NO971546D0 (no) 1997-04-04
FI971404A0 (fi) 1997-04-04
LU92048I2 (fr) 2012-09-20
JPH08208514A (ja) 1996-08-13
NO2009009I1 (no) 2009-05-11
PL186506B1 (pl) 2004-01-30
EP0783893A1 (en) 1997-07-16
EP0783893B1 (en) 2012-04-04
CN101601861A (zh) 2009-12-16

Similar Documents

Publication Publication Date Title
NO971546D0 (no) Reumatoid artritt-middel inneholdende IL-6-antagonist som aktiv bestanddel
DK1334731T3 (da) Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
DE69325130D1 (de) N-sulfonyl-2-oxoindol-derivate mit einer affinität für die vasopressin und/oder ocytocin rezeptoren
RU97108276A (ru) Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента
ATE225772T1 (de) Thrombin-inhibitoren
NO954694D0 (no) Doseringsform for antidepressiva
ATE222237T1 (de) Endothelin-antagonisten
NO942618L (no) Imidazolderivater og deres anvendelse som cytokin-inhibitorer
DE69839992D1 (de) Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff
DK0840606T3 (da) Små di- og trivalente molekyler som selectininhibitorer
ES2044840T3 (es) Composiciones estabilizadas del activador del plasminogeno de tejido humano.
PT97615A (pt) Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
UA27748C2 (uk) Похідні піримідину, що мають активність антагоністів ангіотензину іі, спосіб їх отримання та фармацевтична композиція
MX9200361A (es) Nuevo uso del antagonista de adenosina.
ES2167457T3 (es) Nuevo uso medicinal de un antagonista de 5ht3.
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
NO933524D0 (no) Krystallisk tiagabinhydrokloridmonohydrat samt fremstilling og anvendelse derav
DK144685A (da) Substituerede benzopyraner, fremgangsmaader til fremstilling deraf samt deres anvendelse i laegemidler
YU48915B (sh) Sulfonilkarbamid i postupak za njegovo dobijanje
NO962406L (no) Farmasöytisk formulering for profylakse henholdsvis for behandling av en forgiftning ved fosfororganiske kolinesterasehemmere
ITRM940126A0 (it) Additivo per composizioni cementizie. (caso 154-0241)
EP0661050A4 (en) ANALGESIC.

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: ROACTEMRA - TOCILIZUMAB; REG. NO/DATE: EU108492001-006 20090206

Spc suppl protection certif: 2009009

Filing date: 20090504

Extension date: 20200607

MK1K Patent expired
SPCE Application to extend a supplementary protection certificate (spc)

Free format text: PRODUCT NAME: INTERLEUKIN-6 (IL-6) RESEPTOR ANTISTOFF; NAT. REG. NO/DATE: EU/1/08/492/001/NO-006 20090116; FIRST REG. NO/DATE: EU/1/08/492/001-006 20090116

Spc suppl protection certif: 2018017

Filing date: 20180523

SPCY Withdrawal, rejection or dismissal of a request for extension of a supplementary protection certificate

Free format text: PRODUCT NAME: INTERLEUKIN-6 (IL-6) RESEPTOR ANTISTOFF

Spc suppl protection certif: 2018017

SPCX Expiry of an spc

Free format text: PRODUCT NAME: TOCILIZUMAB

Spc suppl protection certif: 2009009

Effective date: 20200607